274 related articles for article (PubMed ID: 22828717)
1. Evolving molecular targets in the treatment of nonmalignant gastrointestinal diseases.
Katzka DA; Loftus EV; Camilleri M
Clin Pharmacol Ther; 2012 Sep; 92(3):306-20. PubMed ID: 22828717
[TBL] [Abstract][Full Text] [Related]
2. [Pharmacologic treatments of transit disorders].
Manz M; Meier R
Ther Umsch; 2007 Apr; 64(4):227-32. PubMed ID: 17663210
[TBL] [Abstract][Full Text] [Related]
3. Development of drugs for gastrointestinal motor disorders: translating science to clinical need.
Sanger GJ; Alpers DH
Neurogastroenterol Motil; 2008 Mar; 20(3):177-84. PubMed ID: 18257767
[TBL] [Abstract][Full Text] [Related]
4. Pharmacology of the new treatments for lower gastrointestinal motility disorders and irritable bowel syndrome.
Camilleri M
Clin Pharmacol Ther; 2012 Jan; 91(1):44-59. PubMed ID: 22071696
[No Abstract] [Full Text] [Related]
5. Prokinetics in the Management of Functional Gastrointestinal Disorders.
Quigley EMM
Curr Gastroenterol Rep; 2017 Sep; 19(10):53. PubMed ID: 28887755
[TBL] [Abstract][Full Text] [Related]
6. Therapeutic approaches towards the treatment of gastroinstestinal disorders.
Collingwood S; Witherington J
Drug News Perspect; 2007 Mar; 20(2):139-44. PubMed ID: 17440638
[TBL] [Abstract][Full Text] [Related]
7. Ghrelin as a target for gastrointestinal motility disorders.
Greenwood-Van Meerveld B; Kriegsman M; Nelson R
Peptides; 2011 Nov; 32(11):2352-6. PubMed ID: 21453735
[TBL] [Abstract][Full Text] [Related]
8. Stress and the gut: pathophysiology, clinical consequences, diagnostic approach and treatment options.
Konturek PC; Brzozowski T; Konturek SJ
J Physiol Pharmacol; 2011 Dec; 62(6):591-9. PubMed ID: 22314561
[TBL] [Abstract][Full Text] [Related]
9. Current Challenges and Emerging Solutions in Upper GI Disorders: A Brief Report of the 2016 AGA Drug Development Conference.
Howden CW; Vakil NB
Gastroenterology; 2017 Mar; 152(4):e1-e4. PubMed ID: 28147223
[No Abstract] [Full Text] [Related]
10. Mucosal healing in inflammatory bowel disease: impossible ideal or therapeutic target?
Rutgeerts P; Vermeire S; Van Assche G
Gut; 2007 Apr; 56(4):453-5. PubMed ID: 17369375
[TBL] [Abstract][Full Text] [Related]
11. Anti-TNF alpha therapy in the management of extraintestinal manifestation of inflammatory bowel disease.
Andrisani G; Guidi L; Papa A; Armuzzi A
Eur Rev Med Pharmacol Sci; 2012 Jul; 16(7):890-901. PubMed ID: 22953637
[TBL] [Abstract][Full Text] [Related]
12. Tumor necrosis factor-alpha antagonism improves endothelial dysfunction in patients with Crohn's disease.
Schinzari F; Armuzzi A; De Pascalis B; Mores N; Tesauro M; Melina D; Cardillo C
Clin Pharmacol Ther; 2008 Jan; 83(1):70-6. PubMed ID: 17507924
[TBL] [Abstract][Full Text] [Related]
13. New-generation 5-HT4 receptor agonists: potential for treatment of gastrointestinal motility disorders.
Manabe N; Wong BS; Camilleri M
Expert Opin Investig Drugs; 2010 Jun; 19(6):765-75. PubMed ID: 20408739
[TBL] [Abstract][Full Text] [Related]
14. Prokinetic agents.
Reynolds JC; Putnam PE
Gastroenterol Clin North Am; 1992 Sep; 21(3):567-96. PubMed ID: 1516959
[TBL] [Abstract][Full Text] [Related]
15. Appropriateness of immunosuppressive drugs in inflammatory bowel diseases assessed by RAND method: Italian Group for IBD (IG-IBD) position statement.
Caprilli R; Angelucci E; Cocco A; Viscido A; Annese V; Ardizzone S; Biancone L; Castiglione F; Cottone M; Meucci G; Paoluzi P; Papi C; Sturniolo GC; Vecchi M
Dig Liver Dis; 2005 Jun; 37(6):407-17. PubMed ID: 15893279
[TBL] [Abstract][Full Text] [Related]
16. [New treatment options for inflammatory bowel diseases].
Sipponen T; Färkkilä M; Kolho KL
Duodecim; 2014; 130(14):1391-8. PubMed ID: 25158578
[TBL] [Abstract][Full Text] [Related]
17. Pharmacological treatment of functional bowel disorders: any light at the end of the tunnel?
Boeckxstaens GE
Curr Opin Pharmacol; 2008 Dec; 8(6):669-70. PubMed ID: 18835367
[No Abstract] [Full Text] [Related]
18. New pharmacologic therapies in gastrointestinal disease.
Wallace JL; Ferraz JG
Gastroenterol Clin North Am; 2010 Sep; 39(3):709-20. PubMed ID: 20951926
[TBL] [Abstract][Full Text] [Related]
19. Pharmacogenomics in gastrointestinal disorders.
Camilleri M; Saito YA
Methods Mol Biol; 2008; 448():395-412. PubMed ID: 18370239
[TBL] [Abstract][Full Text] [Related]
20. Preclinical gastrointestinal prokinetic efficacy and endocrine effects of the ghrelin mimetic RM-131.
Van der Ploeg L; Laken H; Sharma S; Datta R; Halem H; Dong J; Touvay C; Teillot M; Noonan P; Tartaglia L; Stoner L; Henderson B; Gottesdiener K; Culler M
Life Sci; 2014 Jul; 109(1):20-9. PubMed ID: 24931905
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
